While our screening process showed good results even in the SCD-MCI subgroup analyses (a population with a lower prevalence of tau-PET positivity and thus with lower PPVs for the studied diagnostic tests), the results were substantially better for the all-cause dementia population, which is compatible with the well-described fact that current tau blood biomarkers perform better in advanced stages. This evidence concerns the gene MAPT and dementia.